CNTX CONTEXT THERAPEUTICS INC

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager

Expect to share initial data in the first half of 2026

PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, IL.

The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The study is expected to enroll up to 70 patients.

CTIM-76 Highlights and Near-Term Milestones

  • Dosed first patient in January 2025 and currently dosing cohort 3
  • 7 active trial sites in the United States
  • Expect to share initial data in the first half of 2026

Poster Presentation Details:

Title: A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors

Abstract Number: 

Poster Session: Developmental Therapeutics—Immunotherapy

Date and Time: Monday June 2, 2025, 1:30 PM CDT

Location: Hall A

Poster Board Number: 323b

A copy of the presentation materials will be made available on the “Publications and Posters” section of the Company’s website at .

About CTIM-76

CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on .

About Context Therapeutics®

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit  or follow the Company on  (formerly Twitter) and .

Forward-looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain ASCO presenters to participate in and present at conferences, (ii) our expectation to share initial clinical data in the first half of 2026 for CTIM-76, (iii) the potential benefits, characteristics, safety and side effect profile of our product candidates, (iv) our expectation regarding what the trial is intended to evaluate and the number of patients to be enrolled, (v) the likelihood data will support future development, and (vi) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:

Jennifer Minai-Azary

Chief Financial Officer

Context Therapeutics Inc.



EN
02/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEXT THERAPEUTICS INC

 PRESS RELEASE

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presen...

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, end...

 PRESS RELEASE

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medica...

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors (“Board”). Dr. Cha...

 PRESS RELEASE

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 160,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Conte...

 PRESS RELEASE

Context Therapeutics Reports First Quarter 2025 Operating and Financia...

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025,...

 PRESS RELEASE

Context Therapeutics Announces Chief Medical Officer Transition

Context Therapeutics Announces Chief Medical Officer Transition Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced Dr. Karen Smith, MD, PhD, MBA, LLM as interim Chief Medical Officer (“CMO”). Dr. Smith replaces Dr. Claudio Dansky Ullmann, who will be leaving the Company effective May 10, 2025. Dr. Smith will continue in a dual capac...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch